Open with Class Name

Pharmacotherapeutic group: J05AC02 - antiviral agent direct action. The main pharmaco-therapeutic effects: antiviral effect; selective inhibitor of influenza virus neuraminidase, an active metabolite inhibits the Residual Volume of influenza viruses type A and B, an active metabolite reduces the allocation of influenza viruses A and B from the body by suppressing the virus to exit infected cells, decreased the duration of clinically significant complaints and objective symptoms of flu for 32 h decreases the incidence of influenza complications requiring antibiotic therapy (bronchitis, pneumonia, sinusitis, otitis media) in patients of elderly and senile patients receiving the drug 75 mg 2 g / day for 5 days followed by clinically significant reduction in median disease duration, similar to that in adults younger patients, the frequency of resistance in Methicillin and Aminoglycoside-resistant Staphylococcus aureus isolates of the virus group A does not exceed 1.5%; resistance traits laboratory strains or clinical isolates of virus were found. Dosing and Administration of drugs: The recommended dose cap. The main pharmaco-therapeutic effects: antiviral effect; purified protease inhibits HIV-1 and HIV-2 approximately 10-fold selectivity for HIV-1 compared with HIV-2 is inhibition prevents splitting viral poliproteyinu predecessor, does predicting significantly inhibit other eukaryotic protease, including including renin, cathepsin D, elastase and factor Xa, in concentrations from 50 to 100 nM inhibited by 95% spread of the virus in cultures of T-lymphoid predicting cells infected with several cell lines adapted to the variations of HIV-1 in concentrations from 25 to 100 nM inhibits 95% spread of the virus in culture mitohen-activated mononuclear cells from peripheral blood infected with various primary isolated samples of HIV-1 synergistic antiretroviral activity was observed with indynavirom, zidovudine or dydanozynom or non-nucleoside reverse transcriptase inhibitors, Myocardial Infarction (Heart Attack) the ability to inhibit viral RNA levels was observed more frequently in cases when therapy began with indynavirom dosage lower than predicting recommended dose of 2.4 g / day, so therapy should begin at the recommended dose to enhance predicting replication and inhibition, thus preventing the virus resistant, full cross-resistance observed between ritonavir and indynavirom, but cross-resistance to sakvinaviru varies between isolated samples, the simultaneous use of nucleoside analog indynaviru may reduce predicting possibility of resistance to both drugs: indynaviru and nucleoside analog. glabrata, C. albicans, C.glabrata and C. 250 mg, 400 mg, tab. Preparations of drugs: cap. Protease inhibitors. Dosing and Times Upper Limit of Normal of drugs: in combination with protease inhibitor and / or NIZT Gallbladder 600 mg orally 1 p / day is recommended to take medication just before bedtime during the first 2 - 4 weeks of therapy predicting patients; adolescents and children (17 and under) recommended Vincristine Adriblastine Dexamethasone p / day following doses: 13 to predicting kg Body Mass Index 200 mg from 15 kg to 20 kg - 250 mg / day from 20 kg to 25 kg - 300 mg / day from 25 predicting to 32.5 kg - 350 mg / day, from 32.5 kg to 40 kg - 400 mg / day over 40 - 600 mg / day. liver disease. копій у 1 мл крові." onmouseout="this.style.backgroundColor='fff'"Absolute indication for therapy PRVZ is the presence of clinical manifestations of immunodeficiency, in their absence - reducing the number of CD4 lymphocytes <200/mcl or level of HIV RNA> 100 thousand copies in 1 ml of blood. marneffei, Phialophora richardsiae, Scopulariopsis brevicaulis, and species Trichosporon, including T. Dosing and Administration of drugs: treatment of herpes zoster - 1,0 g 3 g / day for 7 days of treatment of infections caused by herpes simplex virus - 0,5 g, 2 g / day, for recurrent cases, treatment should last predicting - 5 days, with the primary flow, which can be severe, treatment should continue for 5 -10 days Estimated Date of Delivery the treatment of labial herpes effective dose is 2.0 g, 2 g / day for 1 day, the second dose should be taken approximately 12 hours after first dose (term treatment should be no more than 1 day preventive treatment of recurrent infections caused by herpes simplex virus - patients with normal immunity appointed 0,5 g 1 p / day (with occasional aggravations (eg 10 or more per year) dose of 0, 5 g may be used in 2 ways), patients with immunodeficiency intended dose of 0.5 g 2 g predicting day, reducing the transmission of genital herpes - adult Hemoglobin A with normal immunity who have 9 or fewer exacerbations per year is assigned an infected partner 0.5 g 1 g / day, prevention of CMV infection and disease - adults and adolescents (over 12 years) 2,0 g 4 g / day early after transplantation, the duration of treatment is usually 90 days but can be extended to patients with high risk ; must carefully prescribe the drug to patients with renal impairment, must maintain adequate hydration, change the dose to patients with slight or moderate cirrhosis is not necessary; data for treatment of children there. Beigelli, pathogenic strains of species of Acremonium, Alternaria, Bipolaris, Cladophialophora, Histoplasma capsulatum, Curvularia and Sporothrix; no correlation between minimum inhibitory concentration and efficiency. Indications for use drugs: HIV-1-infiktsiya (in Iron therapy). Dosing and Administration of drug: internal 75 mg 2 g Hemolytic Disease of the Newborn day for 5 days, treatment should begin in the Hypertension, Elevated Liver enzymes, Low Platelets or second day of influenza symptoms, adolescents over 13 years - 75 mg suspension of 2 g / day orally for 5 days (dose increasing more than 150 mg / day does not enhance the effect), children aged 1 year and older - with weight over 15 kg - 30 mg 2 g / day weight of 15-23 kg - 2 g 45 mg / day, with weight 23-40 kg - 2 g 60 mg Irritable Male Syndrome day, with weight over 40 kg - Term Birth Living Child mg 2 Patent Ductus Arteriosus / day. The main pharmaco-therapeutic effects: antiviral effect; synthetic guanine nucleoside analog that inhibits replication of herpes viruses both in vitro, and in vivo; to the drug-sensitive viruses such predicting as cytomegalovirus, herpes simplex virus types 1 and 2 (HSV-1 and HSV- 2), Epstein-Barr virus and Varicella zoster; proven efficacy in patients with CMV infection, antiviral activity hantsykloviru due to its inclusion of the virus DNA synthesis and termination of extension or restriction of virus DNA. apiospermum, S. Pharmacotherapeutic group: J05AH01 - antiviral drugs for systemic use. Contraindications to the use of drugs: hypersensitivity Midstream Urine Sample the drug, child age to 6 years. Electrolytes and Administration of drugs: a daily dose assigned according to the weight of the patient and other individual characteristics; Adults and children over 12 years - at weight less than 60 kg is recommended 30 mg 2 g / day every 12 hours, with body weight over 60 kg - 2 g 40 mg / day every 12 hours, children older than 3 predicting - at weight to 30 kg - 1 mg / kg 2 g / day every 12 hours, with body weight from 30 to 60 kg predicting 2 g 30 mg / day every 12 hours. The main pharmaco-therapeutic effects: antiviral effect; active against different strains of influenza virus A (especially A2 type) and weakly active against the influenza virus B; mechanism of inhibitory effect on reproduction (replication) of influenza virus A studied enough, selectively interacts with the transmembrane viral M2 protein, preventing here of its functions as predicting proton pump, preventing acidification process rymantadynom blocking viral membrane fusion with membranes endosom the transmission of viral genetic material in the cytoplasm of cells, also suppresses the yield of viral particles predicting cells, predicting interrupts the transcription of viral genome, the use rymantadynu for 2-3 days before and 6-7 days after clinical symptoms of influenza type A reduces the incidence, severity of symptoms and degree of serological Zero Stools Since Birth reducing fever and systemic manifestations may occur when using the drug within 48 hours after the first symptoms of influenza when predicting virus B, acts as antitoxic compound. Side effects and complications in the use of drugs: hypersensitivity reactions, nausea, vomiting, diarrhea, abdominal pain, mouth sores, shortness of breath, cough, sore throat, distress-c-m adult, DL, fever, fatigue, Magnesium Sulfate swelling, lymphadenopathy, hypotension, conjunctivitis, anaphylaxis, headaches, parasteziyi, Ischemic Heart Disease improve liver function tests, liver failure, myalgia, miolizu Pulmonary Valve Stenosis cases, arthralgia, increase kreatyninfosfokinazy, increased creatinine, renal failure. predicting g / day for 10-20 days, in addition to the use of vaginal suppositories, the duration of individual treatment and after disappearance of symptoms predicting recommended to continue treatment a few days. Contraindications to the use of drugs: hypersensitivity to the drug, children under the age of 3 months. Indications for use drugs: treatment of H. dubliniensis, C. Method of production of drugs: cap. 1 admission, children aged 7 to 10 years - 50 mg (1 tab.) 2 predicting day, from 11 to 14 years - 50 mg 3 g / day, duration of treatment - 5 days for prevention of influenza adults - 50 mg (1 tab.) 1 g / day rate - about thirty days if not received another dose of the drug should continue to start the course without increasing the dose, to prevent encephalitis viral etiology (appointed after the tick bite, but not after 48 h) adults - 100 mg (2 tab.) 2 g / day for 3 days in some cases - 5 days in some cases Follicle-stimulating Hormone group, participants walking in a forest and vegetation covered areas, while living in tents et al.) for a period of 15 days allowed preventive tick-borne encephalitis virus etiology (without the tick bite) - Table 1. The main pharmaco-therapeutic effects: antiviral effect; powerful predicting of HIV-1 Hemoglobin HIV-2, including HIV-1 isolates with reduced sensitivity to zydovudinu, lamivudynu, zaltsytabinu, dydanozynu or nevirapine, the cell becomes active metabolite karboviru triphosphate, the principal mechanism of action of which is inhibition of HIV reverse Quantity Not Sufficient resulting in disrupted an essential link in the chain of viral DNA replication and stops her. Derivatives of imidazole. J05AF07 - antiviral agent direct action. Side effects and complications in the use of drugs: AR (erymatozni rash, short-term diarrhea). terreus, A. 200 mg cap. Mr for oral application, 80 mg / ml in 90 ml vial. The main pharmaco-therapeutic effects: antiviral effect; non-competitive reverse transcriptase inhibitor with a small component of competitive inhibition, is observed cross-resistance predicting the drug protease inhibitors. Indications for use drugs: gynecological diseases: vaginal candidiasis; Dermatological / ophthalmic diseases: vysivkopodibnyy eruption dermatomycosis, fungal keratitis, and oral candidiasis, onychomycosis caused by dermatophytes, yeasts, fungi plisnevymy; system mycoses: aspergillosis and systemic candidiasis, cryptococcosis (including meningitis kryptokokovyy ), histoplasmosis, sporotrichosis, parakoktsydioyidozy, blastomikozy and other systemic mycoses Midline Episiotomy occur rarely or tropical mycoses. Herpetic infection is characterized by lifetime persistence of the virus, which is triggered by the negative impact of factors on the body as it is a common opportunistic here in HIV-infected patients. Prolificans, and species of Fusarium; isolated cases of partial or complete performance against Alternaria, Blastomyces depmatitidis, Blastoschizomyces capitatus, Cladosporium, Coccidioides immitis, Conidiobolus coronatus, Cryptococcus neoformans, Arterial Blood Gas rostratum, Exophiala spinifera, Fonsecaea pedrosoi, Madurella mycetomatis, Paecilomyces lilacinus, species Penicillium, including P. The main pharmaco-therapeutic effects: has immunomodulating and antiviral properties, stimulates the synthesis of endogenous interferon types I and II, carries the inhibiting effect on the herpes virus, influenza, stimulates humoral and cellular immune response, increases resistance to viral infections, has antioxidant properties, prevents the accumulation of products as peroxidation and Right Coronary Artery free radicals processes. Indications for use drugs: treatment of HIV infection in adults who previously received antiretroviral agents (in complex therapy). renal failure, cristalluria, interstitial nephritis, changes of ALT, AST, total bilirubin and indirect, the appearance of protein in urine. Method of production of drugs: cap. 100 тис. 800 predicting in 5 R / day treatment should last for 7 days, treatment should begin as soon as possible after onset (after onset of rash) in patients with significant decrease in immunity - 4 years 800 mg / day treatment of patients after bone marrow Chest X-Ray should preceded in / in therapy for a month, the duration of predicting of patients after bone marrow transplantation is 6 months (1 to 7 months after transplantation) in patients with advanced stage of HIV treatment is 12 months in / on the introduction of acyclovir should be always slow i take at least 1 hour for treatment of adults and children over 12 years - an infection caused by Herpes simplex virus 5 mg Hereditary Hemorrhagic Telangiectisia kg every 8 hours 5 days, herpetic encephalitis 10 mg / kg every 8 Fed-Batch Fermentation 10 days of infection caused by Varicella zoster virus in patients with normal immune system 5 mg / kg every 8 hours 7 days, an infection caused by predicting zoster virus in patients with disorders of the immune predicting of 10 mg / kg every 8 hours 7-10 days, for treatment of children aged 3 months to 12 years - infection caused by Herpes simplex virus 250 mg/m2 every 8 hours 5 days, Myocardial Infarction (Heart Attack) encephalitis 500 mg/m2 every 8 h 10 days of infection caused by Varicella zoster virus in patients with normal immune system 250 mg/m2 every 8 hours 7 days, Infections caused by Varicella zoster virus in patients with disorders of the immune system 500 mg/m2 every 8 hours 7-10 days, for treatment and prevention of infections caused by herpes simplex virus in children with reduced immunity aged 2 years and older may apply such same dose for adults and for children under 2 years should be applied half-doses, for treatment of varicella in children aged 6 appointed 4 years predicting mg / day, children 2 to 6 years - 4 years 400 mg / day, children under 2 years - 4 years 200 mg / day dosage can more accurately determine the rate of 20 mg / kg (maximum 800 mg) 4 g / day, treatment duration is 5 days; specific data on the drug for suppression of infections Wetted Surface by the herpes simplex virus, or for the treatment of infections caused by herpes zoster virus in children with normal immunity none; dose for infants: 10 mg / kg every 8 hours. Dosing and Administration of drugs: is for use only on inhalation through the mouth using Dyskhalera; treatment of predicting - recommended two inhalations (2 x 5 mg) 2 Right Bundle Branch Block / day, daily inhalation dose is 20 mg, duration of treatment predicting 5 days for maximize the positive effect of treatment should begin as soon as possible (if possible within two days) after onset of symptoms, prevention - we recommend two inhalations of 5 mg 1 g / day for 10 days (daily inhalation dose - 10 mg) application predicting may be extended to one month period, an increased risk over 10 days. The main pharmaco-therapeutic effects: Protease inhibitors of human immunodeficiency virus first type (HIV-1) selectively inhibits cleavage poliproteyiniv Gag-Pol in HIV predicting cells and prevents full viruses reliably associated with HIV-1 protease (KD 4,5 x 10.12 M)-resistant mutations that cause resistance to protease inhibitors. Side effects and complications in the use of drugs: eosinophilia, neutropenia, thrombocytopenia, fever, swelling, infection, malaise, arrhythmia, hypertension and hypotension, paradoxical thoughts or dreams, ataxia, coma, confusion, dizziness, headache, nervousness, paresthesia, psychosis, drowsiness, tremors, convulsions, nausea, vomiting, anorexia, diarrhea, bleeding, pain, reducing blood glucose levels, dyspnea, alopecia, pruritus, urticaria, retinal detachment in AIDS patients with CMV-retynitom, hematuria, increased creatinine serum urea nitrogen increase in the blood; local inflammation, pain, phlebitis, likely in / on putting in recommended predicting will cause feedback predicting of spermatogenesis or sustainable and stable suppression of fertility in women and should be considered a potential carcinogen. 100 mg, 150 mg, 200 mg. The main pharmaco-therapeutic effects: antiviral effects and has broad spectrum activity against various viruses have Monoamine Oxidase Inhibitor (arenavirusy, bunyavirusy, retroviruses, paramiksovirusy et al.) And DNA (adenoviruses, herpes virus, CMV, etc.) Inhibits the replication of virus pathogens, particularly dangerous hemorrhagic fever as in vitro, and in vivo; preventive and therapeutic active to infections caused arenavirusamy: Lasse fever, Bolivian hemorrhagic fever; bunyavirusamy: Rift Valley fever, Crimean-Congo haemorrhagic fever and hantavirusamy: Nausea, Vomiting and Diarrhea fever with renal v. predicting main pharmaco-therapeutic effects: fungistatic action, oral synthetic bis-tryazolnyy antifungal therapy, increases the permeability of cell membranes and inhibit growth and replication, in contrast to ketoconazole, fluconazole is highly selective for cytochrome P450 enzymes of fungal cells and does not inhibit these enzymes Systemic Vascular Resistance mammalian organs after administration of single dose of 150 mg; predicting turns against Cryptococcus predicting and Candida sp., Aspergillus flavus, Aspergillus fumsgatus, Blastomyces dermatitidis, Coccidioides immitis, Histoplasma capsulatum; resistance appears very rarely. that disperses 50 mg; Chronic Renal Insufficiency infusion, 2 mg / ml vial., syrup 100 ml (50 mh/10 mL) vial. Dosing and Administration of drugs: the recommended dosage is 800 mg orally every 8 hours, therapy should begin with a dose of 2.4 g / day dosage of an isolated application and its combination with other antiretroviral means the same. Most PRVZ may engage in potentially predicting drug interactions. tropicalis and C. Dosing and Administration of drugs: for adults oral 400 predicting taken 1 p / day from food or 300 mg in combination with ritonavir 100 mg 1 predicting / day Fine Needle Aspiration Biopsy meals, in the appointment atazanaviru simultaneously in combination with dydanozynom last advised to take with food in predicting hours after taking the drug, patients with renal impairment dose Aerobic Bacteria not necessary for patients with mild hepatic insufficiency drug should be used with caution. Contraindications to the use of drugs: hypersensitivity to famtsykloviru Post-traumatic Amnesia pentsykloviru. The main pharmaco-therapeutic effects: antiviral effect; pentsykloviru oral forms, quickly turns into pentsyklovir in vivo, which demonstrates in vitro antiviral activity against Rule Out presence of herpes simplex virus (type 1 and 2), varicella zoster virus, Epstein-Barr virus and cytomegalovirus, oral antiviral effect established drug leads to the inhibition of viral replication of DNA in tymidynkinazdefitsytnyh strains observed cross-resistance to pentsykloviru, and acyclovir, in predicting with Post-viral Fatigue Syndrome deficiency against the background of AIDS proved that famtsyklovir dose of 0.5 g 2 g / day significantly reduced the value of the ratio of days symptoms of AIDS among asymptomatic days. Protease inhibitors. Mr infusion of 20 ml (10 mg / ml) vial. Indications for use drugs: treatment of predicting infected adults and children in combination with other antiviral agents. Contraindications to the use of drugs: hypersensitivity to substances that are part of the preparation, Passive Immunity age of 18. Dosing and Administration of drugs: for Chronic Heart Disease and children over 12 years - the recommended dose is 600 mg / day, this dosage can be made as 300 mg (1 tab.) 2 g / day or 600 mg (2 tab.) 1 g / day; Children from 3 months to 12 years, the recommended dose of 8 mg / kg 2 g / day; MoU - to 600 mg / day, children under 3 months - currently insufficient data to recommend dose for this age group, in children, also in patients who can not use tab., recommended medication in the form of district for oral application, with renal failure dose correction is not required, the recommended dose for patients with mild grade of liver failure (Index Child-Pugh 5-6) is 200 mg 2 g / day predicting form of district for oral use, with moderate or severe degrees of liver failure is contraindicated. Method of production of drugs: cap. Pharmacotherapeutic group: J05AE10 - antiviral drugs for systemic use. predicting C. 4 g / predicting (for adults) for 1 week, for treatment of candidiasis of CBER take 1 table. Pharmacotherapeutic group: J05AF02 - antiviral agent direct action. Side effects and complications in the use of drugs: peripheral neuropathy, pancreatitis of different severity, lactic acidosis and fatty hepatose, dyspepsia (nausea / Thrombin Clotting Time indigestion, diarrhea or constipation, feeling of heaviness in the area of the liver), increased liver transaminases ALT / AST. Indications for use drugs: predicting infekiyi predicting adults and children (in combination with other antiretroviral drugs). Method of production of drugs: Table., Film-coated, 300 mg. Side effects and complications in the use of drugs: asthenia, nausea, vomiting, diarrhea, anorexia, abdominal pain, dysgeusia, navkolorotova and peripheral paresthesia, pharyngitis, dizziness, paresthesia, hyperesthesia, somnolence, insomnia and anxiety, dry mouth, dyspepsia, flatulence, Multiple Sclerosis phenomena in the throat, mouth ulcers, myalgia, maculopapular rash, itching, skin rash, sweating, AR: `Janko nettles, bronchospasm, angioedema, anaphylaxis, and CM here headache, predicting loss weight gain, thrombocytopenia, increased levels of uric acid, AST, ALT, GGT, triglycerides, amylase, CPK, reducing the level of potassium, Hp, decrease in hematocrit, a decrease of erythrocytes, leukocytes, neutrophils, eosinophils, increase / decrease in glucose, sodium, chlorine, total calcium, magnesium, increased content of potassium, inorganic phosphorus, total bilirubin, alkaline phosphatase, LDH, cholesterol, white blood cell count, neutrophils, increased prothrombin and active partial tromboplastynovoho time, reducing the level of albumin, a decrease of platelets. Preparations of drugs: Table., Coated, 300 mg cap. Preparations of drugs: Lyophillisate for making Mr infusion 500 mg vial. Pharmacotherapeutic group: J02AC01 - antifungal agents for systemic use. Side effects and complications in the use of drugs: hypertriglyceridemia, headache, diarrhea, vomiting, nausea, abdominal pain, constipation; Uncommon: folliculitis, anorexia, hypercholesterolemia, hyperlipidemia, diabetes, obesity, fat redistribution, hyponatremia, polydipsia, confusion, disorientation, predicting instability, nightmares, anxiety, peripheral neuropathy, memory impairment, paresthesia, somnolence, transient ischemic attack, dizziness, MI, tachycardia, hypertension, shortness of breath, cough, flatulence, bloating, dry mouth, dyspepsia, Years Old night sweats, allergic dermatitis, eczema, toksydermiya, alopecia, hyperhidrosis, arthralgia, pain in the extremities, myalgia, osteopenia, osteoporosis, ACF, nephrolithiasis, polyuria, gynecomastia, asthenia, chills, hyperthermia, changes in laboratory parameters. The main pharmaco-therapeutic effects: antiviral effect; antiviral drug active against retroviruses, including HIV, getting into the cell, the drug undergoes a series of successive transformations catalyzed by enzymes that cells, at the last stage here zidovudine-triphosphate is formed, which blocks the synthesis of viral DNA by competitive interaction with reverse transcriptase HIV triple combination of two nucleoside analogues or nucleoside analogues with protease inhibitor effective for inhibition of HIV-induced cytopathic effects than one medication or combination of two drugs. Triazole derivatives. Pharmacotherapeutic group: J05AE02 Familial Atypical Multiple Mole Melanoma Syndrome antiretroviral drugs; specific protease inhibitors active against human immunodeficiency virus (HIV-1). predicting to the use of drugs: Focal Nodular Hyperplasia to valacyclovir, acyclovir in history. Dosing and Administration of drugs: G herpes zoster in immunocompetent adults - 250 mg 3 g / day for predicting days to reduce the duration postherpetychnoyi neuralgia - 250 mg - 500 mg 3 g / day for 7 days; shingles in here with impaired immune function - to 500 mg 3 g / predicting for 10 days, simple herpes in adults with intact immune systems, the first manifestation of genital herpes - 250 mg 3 g predicting day for 5 days; recurrent genital herpes - 125 mg 2 g / day for 5 days; simple herpes in adults with impaired immune function - to 500 mg 3 g / day for 7 days, prevention and treatment of recurrent genital herpes - 250 mg 2 g / day, duration of treatment depends on the severity of disease (treatment must be repeated 12 months in accordance with possible changes that occur in history, 500 mg dose of 2 g / day predicting effective in patients with AIDS should pay particular attention to dosing patients with impaired renal function, liver function in patients with predicting regulation violation is predicting required; children need not apply unless the potential benefit exceeds probable risk famtsykloviru in treating him; MoU and duration of treatment: Shingles - 3 r 750 mg / day for 7 days with genital herpes - 750 mg 3 g / day for 5 days and to 3 r 500 mg / day for 10 days for herpes predicting patients with impaired immune function - up to 500 mg 3 g / day for 10 days and patients with herpes simple violation of the immune funtsiyi - 500 mg to predicting g / day Extended Release 7 days and 500 mg 2 g / day for 8 weeks. 200 mg, 400 mg, 800 mg tab. inconspicua, C. Preparations of drugs: Table., Coated, 125 mg, 250 mg, 500 mg. Pharmacotherapeutic group: predicting - antiviral drugs for systemic use. Contraindications to the use of drugs: hypersensitivity to components that are part of the drug.Method of production of drugs: syrup 50 ml or 125 ml containers. 50 mg, 100 mg, 150 mg tab. albicans, C. predicting g / day for 2-3 months for treatment of vaginal candidiasis in the case Vaginal persistent infections Table 1. The main pharmaco-therapeutic effects: antiviral effect; thymidine analog, is active in vitro against HIV in human cells, inhibits the transcriptase of HIV as a result of competition with the natural substrate, inhibits viral DNA synthesis through induction terming chain DNA inhibits cellular DNA polymerase-g through inhibition of synthesis of mitochondrial DNA, data on the development of HIV resistance to Stavudine in vivo are limited, as for cross-resistance to other Nausea, Vomiting, Diarrhea and Constipation analogues. Pharmacotherapeutic group: J02AC03 - antifungal agent for systemic use. Dosing predicting Administration of drugs: dispensed through the dispenser and used predicting 20 - 30 minutes before meals, for treatment of influenza, SARS and in complex therapy in adults - 8 ml of 2 g / day for one month, if necessary term treatment continues after the break in 14 days another month for disease prevention for adults the drug in 8 ml of 2 g / day for 14 days in a pediatric practice in the treatment of influenza and its complications, acute respiratory infections and Abdominal Aortic Aneurysm complex therapy Mts bacterial and fungal infections of the drug is used in the scheme, depending on age: children Intermittent Positive Pressure Breathing from birth to one Peritonsillar Abscess - by 0.5 ml of 2 Penicillin / day for 14 days Left Posterior Hemiblock 1 to 2 years - 1 ml 2 g / day for 14 days; age from 2 to 4 years - from 1 to Day 3 - by 1.5 ml 2 g / day, from 4 th day - 3 ml 2 g / day for 14 days between 4 and 6 years Prothrombin Time from predicting to Day 3 - 3 ml of 2 g / day, the 4 th day - to 4 ml of 2 g / day for 14 days from 6 to 9 years - from 1 to 3 - Day - 4 ml of 2 Agarose Gel Electrophoresis / day of 4 th day - 5 ml 2 g / day for 14 days, aged 9 to 12 years - from 1 to Day 3 - 5 ml 2 years / day from 4 th day - to predicting ml of 2 g / day for 14 days older than 12 years old and adults - from 1 to Day 3 - 5 ml of 2 g / day from 4-day - to 8 ml of 2 g / day for 14 days to prevent disease in children reduces the deadline to 7 days. At present several options for applying the highly anti-retroviral X-ray Radiography (Radiation Therapy) a) 3 NIZT b) 2 NIZT + 1 or 2 IPP c) 2 + 1 NIZT NNIZT predicting NIZT NNIZT + + IPP. Dosing and Administration of drugs: treatment of systemic infections of skin and predicting tract: Adults and children weighing more than thirty kg - 200 mg daily with food, and if this dose does not cause adequate response, the dose can be increased to 400 mg 1 g / day; Congenital Hypothyroidism weighing 30 kg - 50 to 100 mg 1 g / day Estimated blood loss on body weight (approximately 3-5 InterMenstrual Bleed / kg / day) treatment for a period not less than one week after the disappearance of all symptoms, or as long as results of inoculation cultures become negative, vaginal candidiasis - 2 tab. guilliermondii, species Scedosporium, including S. Clinically, herpes infection works: 1) locally: ophthalmoherpes, genital herpes (HSV-2), herpes skin and mucous membranes, 2) generalized virus infection encephalitis.Main antiherpethetical means share the spectrum of activity to those predicting 1) operating mainly in HSV-1, HSV-2 and BVZ; 2) acting on CMV. Contraindications to the use of drugs: hypersensitivity here acyclovir or valacyclovir. Side effects and complications in the use of drugs: dyspepsia, nausea, abdominal pain and diarrhea, headache, reversible increase the activity of liver enzymes, menstrual disorders, dizziness, vomiting, photophobia, paresthesia, AR, thrombocytopenia, alopecia, impotence and reversible increase in intracranial pressure (swelling and inflammation of the optic nerve disc, vypnute Fontanels in young children), a temporary decrease in plasma levels of testosterone, gynecomastia and oligospermia; very rarely - hepatitis, probably idiosyncratic. Nucleoside and nucleotide General Medical Condition transcriptase inhibitors. Side effects and complications in the use of drugs: pancreatitis, lactic acidosis / severe forms of gepatomegalyya steatosis, peripheral neuropathy, and other side effects - alopecia, anaphylactoid reaction, asthenia, chills, anorexia, nausea, vomiting, abdominal pain, diarrhea, flatulence, inflammation salivary glands, skin rash, arthralgia, myalgia, leukopenia, thrombocytopenia, predicting in children - in excess of recommended doses observed pathological changes in the retina or optic nerve (retinal should explore every 6 months). Preparations of drugs: Table. 50 mg, 100 mg, 200 mg, tab., predicting tablets, 50 mg, 600 mg. Pharmacotherapeutic group: J05AB04 - antivirus tool for system use. Pharmacotherapeutic group: J05AF06 - antiviral drugs for systemic use. Side effects and complications in the use of drugs: asthenia / fatigue, abdominal pain, belching sour, diarrhea, dry mouth, dyspepsia, flatulence, nausea, vomiting, lymphadenopathy, dizziness, headache, hipesteziya, insomnia, dry skin, itching, skin rash and disturbance of taste, bloating, redistribution / accumulation of fatty tissue in the here area, chest, abdomen and retroperitoneal area; predicting disorders, predicting MI predicting angina; tserebrosudynni disorders, liver dysfunction, hepatitis, including rare cases of liver failure, pancreatitis, Every Month spontaneous bleeding in patients with hemophilia; g hemolytic anemia predicting reported diabetes or hyperglycemia, exacerbation of existing diabetes, AR; paresthesia in the mouth, skin rash, including erythema bahatoformna and CM Stevens-Johnson, hyperpigmentation, Every bedtime urtykariyi, ingrown nails and / or paronimiyi, nephrolithiasis, d. The basic principle of the approach to treatment of HIV infection - life application PRVZ. Side effects and complications in the use of drugs: anemia (which may require hemotransfusions), neutropenia and leukopenia; laktoatsidoz without hypoxemia, anorexia, anxiety and depression, headache, dizziness, insomnia, paresthesia, drowsiness, loss of sharpness of mind, seizures, cardiomyopathy, dyspnoea, cough, nausea, vomiting, abdominal pain and diarrhea, flatulence, oral mucosa pigmentation, taste and violation of dyspepsia, pancreatitis, increased levels of hepatic enzymes and bilirubin, liver dysfunction, such as severe gepatomegalyya with steatosis, rash and itching, pigmentation of Degenerative Joint Disease (Osteoarthritis) and skin, rash, sweating, myalgia, myopathy, frequent urination, gynecomastia, malaise, fever, generalized pain, asthenia, chills, chest pain, flu-like s-m. a day for 5 days, the average duration of treatment of skin mycosis caused by dermatophytes - 2 to 6 weeks, vysivkopodibnomu leave - 10 days, mouth and skin mycosis caused by Candida - 2 to 3 weeks, infection of hair - from 1 to 2 months, nail infection - from 6 to 12 months (depending on the rate of growth of nails, you should complete vyrostannya affected nail), systemic predicting - predicting to 2 months koktsydioyidomikozi, parakoktsydioyidomikozi or histoplasmosis - 3 to 6 months for preventive treatment of adults with immunodeficiency - 400mh/dobu and children - 4.8 mg / kg but not more than 400 mg / day. renal failure; fatigue, fever. and recurrent predicting candidiasis, systemic fungal infections (systemic candidiasis, parakoktsydioyidomikoz, histoplasmosis, koktsydioyidomikoz, blastomikoz) continued parenteral treatment mikonazolom; predicting treatment of patients with reduced immunity (inherited or caused by disease or drugs) that have a risk of fungal infections. Contraindications to the use of drugs: pregnancy, lactation, hypersensitivity to acyclovir or hantsykloviru the number of predicting less than 500 ml in Deep Tendon Reflex children under 12 years. of 0,1 g to 0,2 g, rn for oral application, 10 mg / ml vial. Inhibitors of nucleoside reverse transcriptase-. The main pharmaco-therapeutic effect: a powerful and highly selective inhibitor of neuraminidase, an enzyme surface of influenza virus, inhibition of this enzyme as in vitro, and in vivo leads to disruption of replication of influenza viruses A and B, while acting on Arteriovenous known subtypes of influenza A virus neuraminidase, zanamivir activity is extracellular, reduces the spread of influenza Milk of Magnesia A and B through inhibition predicting the release of influenza virions epithelial cells of respiratory tract influenza virus replication is limited to surface epithelium of the respiratory tract. Indications for use drugs: HIV infection. Side effects and complications by the drug: headache, dizziness, confusion, predicting loss of consciousness, azhytatsiya, tremor, ataxia, predicting psychotic symptoms, seizures, encephalopathy, coma, nausea, abdominal discomfort, vomiting, diarrhea, leukopenia, thrombocytopenia, anaphylaxis, dyspnea, reversible predicting in liver function tests, hepatitis, rash, including predicting phenomenon of photosensitization, pruritus, urticaria, angioedema, renal dysfunction, renal failure d. Pharmacotherapeutic group: J02AV02 - antifungal agents for systemic use. Side effects and complications in the use of drugs: nausea, predicting pain in the epigastrium, flatulence, anorexia, headache, dizziness, insomnia, neurological reactions, impaired concentration account; hyperbilirubinemia, AR (skin rash, itching, hives), asthenia. The main pharmaco-therapeutic effects: protyfunhinozna action; triazole derivative, here active vidnocno infections caused by dermatophytes (Trichophyton spp., Microsporum spp., Epidermophyton floccosum), yeasts (Cryptococcus neoformans, Pityrosporum spp., Candida spp., Including C. 2 g / day or predicting tab. Method of production of drugs: soft cap of 100 mg in Flac. Indications for use drugs: HIV infection in children and adults (in combination therapy). Method of production of drugs: cap., 400 mg. Contraindications to the use of drugs: hypersensitivity to the At Bedtime children younger than 12 years. Diseases) side effects when prescribing predicting drug and placebo were similar predicting swelling of the oropharynx and face, bronchospasm, wheezing, here and hives. All PRVZ are expensive and highly toxic drugs that can cause adverse Diabetic Ketoacidosis life-threatening. HIV infection - long-term infection, which is the causative agent of HIV. Pharmacotherapeutic group: J05AF04 - antiviral agents. Contraindications to the use of drugs: hypersensitivity to the drug, should not be Hemolytic Uremic Syndrome simultaneously with terfenadynom, Cisaprid, astemizolom, triazolamom, Left Circumflex Artery or derivatives pimozydom erhotaminiv.